Compile Data Set for Download or QSAR
maximum 50k data
Found 228 Enz. Inhib. hit(s) with Target = 'TGF-beta receptor type-1 [162-503]'
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451769(US10710980, Example 1 | US10947218, Example 1)
Affinity DataIC50:  560nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451769(US10710980, Example 1 | US10947218, Example 1)
Affinity DataIC50:  560nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM518855(US11160797, Example 1 | US11160797, Example 26 | U...)
Affinity DataIC50:  580nMAssay Description:Example 54:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 9 ul. Dose-response curves were ge...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM518859(US11160797, Example 2)
Affinity DataIC50:  610nMAssay Description:Example 54:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 9 ul. Dose-response curves were ge...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM522065(US11160797, Example 3)
Affinity DataIC50:  660nMAssay Description:Example 54:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 9 ul. Dose-response curves were ge...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM522124(US11160797, Example 32)
Affinity DataIC50:  690nMAssay Description:Example 54:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 9 ul. Dose-response curves were ge...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM522097(US11160797, Example 5)
Affinity DataIC50:  720nMAssay Description:Example 54:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 9 ul. Dose-response curves were ge...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451789(US10710980, Example 21 | US10947218, Example 21)
Affinity DataIC50:  900nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451789(US10710980, Example 21 | US10947218, Example 21)
Affinity DataIC50:  900nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM522135(US11160797, Example 43)
Affinity DataIC50:  1.00E+3nMAssay Description:Example 54:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 9 ul. Dose-response curves were ge...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451805(US10710980, Example 37 | US10947218, Example 37)
Affinity DataIC50:  1.10E+3nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451805(US10710980, Example 37 | US10947218, Example 37)
Affinity DataIC50:  1.10E+3nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451795(US10710980, Example 27 | US10947218, Example 27)
Affinity DataIC50:  1.30E+3nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451795(US10710980, Example 27 | US10947218, Example 27)
Affinity DataIC50:  1.30E+3nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451793(US10710980, Example 25 | US10947218, Example 25)
Affinity DataIC50:  1.40E+3nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451822(US10710980, Example 51 | US10947218, Example 51)
Affinity DataIC50:  1.40E+3nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451793(US10710980, Example 25 | US10947218, Example 25)
Affinity DataIC50:  1.40E+3nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451822(US10710980, Example 51 | US10947218, Example 51)
Affinity DataIC50:  1.40E+3nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM522131(US11160797, Example 39)
Affinity DataIC50:  1.40E+3nMAssay Description:Example 54:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 9 ul. Dose-response curves were ge...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451806(US10710980, Example 38 | US10947218, Example 38)
Affinity DataIC50:  1.50E+3nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451806(US10710980, Example 38 | US10947218, Example 38)
Affinity DataIC50:  1.50E+3nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM522117(US11160797, Example 25)
Affinity DataIC50:  1.50E+3nMAssay Description:Example 54:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 9 ul. Dose-response curves were ge...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451785(US10710980, Example 17 | US10947218, Example 17)
Affinity DataIC50:  1.60E+3nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451807(US10710980, Example 39 | US10947218, Example 39)
Affinity DataIC50:  1.60E+3nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451785(US10710980, Example 17 | US10947218, Example 17)
Affinity DataIC50:  1.60E+3nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451807(US10710980, Example 39 | US10947218, Example 39)
Affinity DataIC50:  1.60E+3nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451836(US10710980, Example 65 | US10947218, Example 65)
Affinity DataIC50:  1.70E+3nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451836(US10710980, Example 65 | US10947218, Example 65)
Affinity DataIC50:  1.70E+3nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451801(US10710980, Example 33 | US10947218, Example 33)
Affinity DataIC50:  1.80E+3nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451801(US10710980, Example 33 | US10947218, Example 33)
Affinity DataIC50:  1.80E+3nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM522113(US11160797, Example 21)
Affinity DataIC50:  1.80E+3nMAssay Description:Example 54:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 9 ul. Dose-response curves were ge...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451787(US10710980, Example 19 | US10947218, Example 19)
Affinity DataIC50:  1.85E+3nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451787(US10710980, Example 19 | US10947218, Example 19)
Affinity DataIC50:  1.85E+3nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451780(US10710980, Example 12 | US10947218, Example 12)
Affinity DataIC50:  1.90E+3nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451780(US10710980, Example 12 | US10947218, Example 12)
Affinity DataIC50:  1.90E+3nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM522116(US11160797, Example 24)
Affinity DataIC50:  1.90E+3nMAssay Description:Example 54:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 9 ul. Dose-response curves were ge...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451824(US10710980, Example 53 | US10947218, Example 53)
Affinity DataIC50:  2.00E+3nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451824(US10710980, Example 53 | US10947218, Example 53)
Affinity DataIC50:  2.00E+3nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451771(US10710980, Example 3 | US10947218, Example 3)
Affinity DataIC50:  2.13E+3nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451771(US10710980, Example 3 | US10947218, Example 3)
Affinity DataIC50:  2.13E+3nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451770(US10710980, Example 2 | US10947218, Example 2)
Affinity DataIC50:  2.17E+3nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451770(US10710980, Example 2 | US10947218, Example 2)
Affinity DataIC50:  2.17E+3nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451773(US10710980, Example 5 | US10947218, Example 5)
Affinity DataIC50:  2.20E+3nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451773(US10710980, Example 5 | US10947218, Example 5)
Affinity DataIC50:  2.20E+3nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451779(US10710980, Example 11 | US10947218, Example 11)
Affinity DataIC50:  2.40E+3nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451779(US10710980, Example 11 | US10947218, Example 11)
Affinity DataIC50:  2.40E+3nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM522140(US11160797, Example 48)
Affinity DataIC50:  2.40E+3nMAssay Description:Example 54:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 9 ul. Dose-response curves were ge...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM522142(US11160797, Example 50)
Affinity DataIC50:  2.40E+3nMAssay Description:Example 54:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 9 ul. Dose-response curves were ge...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451772(US10710980, Example 4 | US10947218, Example 4)
Affinity DataIC50:  2.45E+3nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451772(US10710980, Example 4 | US10947218, Example 4)
Affinity DataIC50:  2.45E+3nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 228 total ) | Next | Last >>
Jump to: